There are 2789 resources available
790P - Extracellular traps of the circulating neutrophils in CIN and cervical cancer
Presenter: Tatyana Abakumova
Session: ePoster Display
867P - A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
Session: ePoster Display
794P - Comparative study of effectiveness of Pap smear and visual inspection with acetic acid for screening of premalignant and malignant lesion of cervix in a tertiary care setup
Presenter: Meena Kakollu
Session: ePoster Display
908P - Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Presenter: Yuan-Kai Shi
Session: ePoster Display
870P - Comparison of PD-L1 and VISTA expression levels in head and neck cancers in primary and recurrent tumor tissue after radiotherapy/chemoradiotherapy
Presenter: Görkem Yazıcı Şener
Session: ePoster Display
871P - Uptake of concurrent chemoradiation in stage 2 nasopharyngeal cancer (NPC): A population-based outcomes study
Presenter: Teng Hwee Tan
Session: ePoster Display
981P - Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Presenter: Sarwan Bishnoi
Session: ePoster Display
982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer
Presenter: jing xie
Session: ePoster Display
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display